Lucid Diagnostics (LUCD) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Lucid Diagnostics (NASDAQ: LUCD):

• 3/30/2026 – Lucid Diagnostics had its “buy” rating reaffirmed by BTIG Research. They now have a $2.50 price target on the stock.
• 3/28/2026 – Lucid Diagnostics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/26/2026 – Lucid Diagnostics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $3.00 price target on the stock.
• 3/14/2026 – Lucid Diagnostics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/28/2026 – Lucid Diagnostics was upgraded by Wall Street Zen from “sell” to “hold”.

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.